Mereo BioPharma Group plc Announces 2024 Annual General Meeting Details

TL;DR

<b>Mereo BioPharma Group plc will hold its 2024 Annual General Meeting on May 23, 2024, in London, with details provided for both ordinary shareholders and ADS holders.</b>

AI Summary

Mereo BioPharma Group plc (MREO) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. The 2024 Annual General Meeting (AGM) of Mereo BioPharma Group plc will be held on Thursday, May 23, 2024, at 2:00 p.m. British Summer Time. The meeting will take place at 5th Floor, One Cavendish Place, London W1G 0QF, United Kingdom. Shareholders registered as of April 18, 2024, are eligible to attend or appoint a proxy. Information relevant to holders of American Depositary Shares (ADSs) is included. Ordinary shareholders are encouraged to inform the Company's registrar, Link Group, in advance by submitting a proxy vote electronically.

Why It Matters

For investors and stakeholders tracking Mereo BioPharma Group plc, this filing contains several important signals. This filing provides shareholders with the official notice and details for the upcoming AGM, outlining the date, time, and location, as well as the process for voting and attending. It ensures compliance with regulatory requirements for public companies to inform shareholders about important corporate events like the annual general meeting.

Risk Assessment

Risk Level: low — Mereo BioPharma Group plc shows low risk based on this filing. The filing is a routine proxy statement for an annual general meeting and does not contain significant new financial or operational information that would indicate high risk.

Analyst Insight

Shareholders should review the proxy statement to understand the resolutions to be voted on and to exercise their voting rights, either in person or by proxy.

Key Numbers

• 2:00 p.m. BST — AGM Time (Time of the 2024 Annual General Meeting)
• 9:00 a.m. EST — AGM Time (EST) (Equivalent time in Eastern Standard Time)

Key Players & Entities

• Mereo BioPharma Group plc (company) — Registrant and company name
• May 23, 2024 (date) — Date of the AGM
• April 18, 2024 (date) — Record date for shareholders
• Link Group (company) — Company's registrar
• London (location) — Location of the AGM

FAQ

Risk Factors

• Compliance with SEC Filing Requirements [low — regulatory]: The company must file a definitive proxy statement (DEF 14A) in accordance with Section 14(a) of the Securities Exchange Act of 1934 to solicit proxies from shareholders for its annual general meeting.

Key Dates

• 2024-05-23: Annual General Meeting — Shareholders will vote on proposed resolutions.
• 2024-04-18: Record Date — Determines eligibility to receive proxy materials and vote.
• 2024-04-24: Filing Date — Date the DEF 14A was filed with the SEC.

Glossary

AGM

Annual General Meeting (The primary purpose of this filing is to provide information and solicit votes for the company's AGM.)

DEF 14A

Definitive Proxy Statement (This is the official filing type for soliciting shareholder votes for meetings.)

ADS

American Depositary Share (The filing addresses holders of ADSs, which represent ownership in the company's ordinary shares.)

Filing Documents

• d820524ddef14a.htm (DEF 14A) — 422KB
• g820524dsp013.jpg (GRAPHIC) — 160KB
• g820524dsp014.jpg (GRAPHIC) — 291KB
• g820524g55k19.jpg (GRAPHIC) — 69KB
• 0001193125-24-108454.txt (&nbsp;) — 1139KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 30 TRANSACTIONS WITH RELATED PERSONS 32 EXECUTIVE OFFICERS OF THE COMPANY 34

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 35 AUDIT AND RISK COMMITTEE REPORT 40 DELIVERY OF PROXY MATERIALS 42 ADDITIONAL INFORMATION 43 FORM OF PROXY FOR ORDINARY SHAREHOLDERS A-1 i Table of Contents Mereo BioPharma Group plc 4 th Floor, One Cavendish Place, London, W1G 0QF, United Kingdom Registered Company No. 09481161 PROXY STATEMENT FOR THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON, THURSDAY MAY 23, 2024 INFORMATION CONCERNING PROXY SOLICITATION AND VOTING We have sent you this proxy statement and the enclosed form of proxy because the Board of Directors of Mereo BioPharma Group plc (referred to herein as the Company , Mereo , we , us or our ) is soliciting your proxy to vote at our annual general meeting of shareholders (referred to herein as the Meeting or the AGM ) to be held on Thursday, May 23, 2024, at 2:00 p.m. (British Summer Time) (9:00 a.m. Eastern Standard Time) , at 5th Floor, One Cavendish Place, London W1G 0QF, United Kingdom. This proxy statement summarizes information about the proposals to be considered at the Meeting and other information you may find useful in determining how to vote. The form of proxy is the means by which you actually authorize another person to vote your shares in accordance with your instructions. In addition to solicitations by mail, our directors, officers and regular employees, without additional remuneration, may solicit proxies by telephone, e-mail, internet and personal solicitation. All costs of solicitation of proxies will be covered by us. We are mailing the Notice, this proxy statement and the form of proxy to our ordinary shareholders of record as of April 18, 2024 (being the latest practicable date before the circulation of this document) for the first time on or about April 24, 2024. We are also including our annual report on Form 10-K for the year ended December 31, 2023 (the Annual Report on Form 10-K ). This includes mailing or supplying our proxy materials, inclu

View Full Filing

View this DEF 14A filing on SEC EDGAR